Pulmonary targeting of nanoparticle drug matrices

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 23, Issue 6, 2010, Pages 343-353

  Dandekar, Preshit ^a,b   Venkataraman, Chandra ^a   Mehra, Anurag ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY BOMBAY   (India)

^b University of California   (United States)

Author keywords

medical inhalation; pulmonary delivery; radial diffusion of nanoparticles; size dependent deposition; two dimensional transport; whole lung model

Indexed keywords

INSULIN; NANOPARTICLE;

ARTICLE; BREATHING; BREATHING RATE; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG TARGETING; DRUG TRANSPORT; INHALATION; LUNG; PARTICLE SIZE; SEDIMENTATION;

ADMINISTRATION, INHALATION; BIOLOGICAL TRANSPORT; DIFFUSION; DRUG CARRIERS; HUMANS; INSULIN; LUNG; MODELS, BIOLOGICAL; NANOPARTICLES; PHARMACEUTICAL PREPARATIONS; RESPIRATION;

EID: 78649913362     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2009.0784     Document Type: Article

References (39)

1. Borm PJ, and Kreyling W: Toxicological hazards of inhaled nanoparticles\potential implications for drug delivery. J Nanosci Nanotechnol. 2004;4:521-531.
2. Williams J, Lansdown R, Sweitzer R, Romanowski M, LaBell R, Ramaswami R, and Unger E: Nanoparticle drug delivery system for intravenous delivery of topoisomerase inhibitors. J Control Release. 2003;91:167-172.
3. Jani PU, McCarthy DE, and Florence AT: Nanosphere and microsphere uptake via Peyer's patches: observation of the rate of uptake in the rat after a single oral dose. Int J Pharm. 1992;86:239-246.
4. Azarmi S, Roa WH, and Lobenberg R: Targeted delivery of nanoparticles for the treatment of lung diseases. Adv Drug Deliv Rev. 2008;60:863-875.
5. Yang W, Peters JI, and Williams III RO: Inhaled nano-particle\a current review. Int J Pharm. 2008;356:239-247.
6. Pandey R, Sharma A, Zahoor A, Sharma S, Khuller GK, and Prasad B: Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother. 2003;52:981-986.
7. Huang Y and Wang C: Pulmonary delivery of insulin by liposomal carriers. J Control Release. 2006;113:9-14.
8. Liu J, Gong T, Fu H, Wang C, Wang X, Chen Q, Zhang Q, He Q, and Zhang Z: Solid lipid nanoparticles for pulmonary delivery of insulin. Int J Pharm. 2008;356:333-344.
9. Lauweryns JM, and Baert JH: Alveolar clearance and the role of the pulmonary lymphatics. Am Rev Respir Dis. 1977; 115:625-683.
10. Stahlhofen W, Rudolf JG, and James AC: Intercomparison of experimental regional aerosol deposition data. J Aerosol Med. 1989;2:285-308.
11. Yeh H, and Schum GM: Models of human lung airways and their application to inhaled particle deposition. Bull Math Biol. 1980;42:461-480.
12. Hoffmann W, and Koblinger L: Monte Carlo modeling of aerosol deposition in human lungs. Part II: Deposition fractions and their sensitivity to parameter variations. J Aerosol Sci. 1990;21:675-688.
13. Hirst PH, Bacon RE, Pitcairn GR, Silvasti M, and Newman SP: A comparison of the lung deposition of budesonide from Easyhaler, Turbuhaler and pMDI plus spacer in asthmatic patients. Respir Med. 2001;95:720-727.
14. Farr SJ, Schuster JA, Lloyd P, Lloyd LJ, Okikawa JK, and Rubsamen RM: AERx\development of a novel liquid aerosol delivery system: concept to clinic. Respir Drug Deliv V. 1996;1:175-186.
15. Zhang Z, Kleinstreuer C, and Kim CS: Cyclic micron-size particle inhalation and deposition in a triple bifurcation lung airway model. J Aerosol Sci. 2002;33:257-281.
16. Jin HH, Fan JR, Zeng MJ, and Cen KF: Large eddy simulation of inhaled particle deposition within the human upper respiratory tract. J Aerosol Sci. 2007;38:257-268.
17. Kleinstreuer C, Zhang Z, Li Z, Roberts WL, and Rojas C: A new methodology for targeting drug-aerosols in the human respiratory system. Int J Heat Mass Transf. 2008;51:5578-5589.
18. Egan MJ, and Nixon W: A model of aerosol deposition in the lung for use in inhalation dose assessments. Radiat Protein Dosim. 1985;11:5-17.
19. Clark AR, and Egan MJ: Modeling the deposition of inhaled powdered drug aerosols. J Aerosol Sci. 1994;25:175-186.
20. Mitsakou C, Helmis C, and Housiadas, C: Eulerian modeling of lung deposition with sectional representation of aerosol dynamics. J Aerosol Sci. 2005;36:75-94.
21. Ingham DB: Diffusion of disintegration products of radioactive gases in circular and flat channels. J Aerosol Sci. 1975; 6:395-402.
22. Beeckmans JM: The deposition of aerosols in the respiratory tract\I. Mathematical analysis and comparison with experimental data. Can J Physiol Pharmacol. 1965;43:157-172.
23. Yeh H: Use of a heat transfer analogy for a mathematical model of respiratory tract deposition. Bull Math Biol. 1974; 36:105-116.
24. Weibel ER: Morphology of the Human Lung. Academic Press, New York.
25. Chan TL, and Lippmann M: Experimental measurements and empirical modeling of the regional deposition of inhaled particles in humans. Am Ind Hyg Assoc J. 1980;41:399-409.
26. Resnick DJ, Gold RL, and Lee-Wong M: Physicians' metered dose inhaler technique after a single teaching session. Ann Allergy Asthma Immunol. 1996;76:145-148. (Pubitemid 26064444)
27. Ernst P: Inhaled drug delivery: a practical guide to prescribing inhaler devices. Can Respir J. 1998;5:180-183.
28. Scheuch G, Kohlhaeufl MJ, Brand P, and Siekmeier R: Clinical perspectives on pulmonary systemic and macro-molecular delivery. Adv Drug Deliv Rev. 2006;58:996-1008.
29. Furtado S, Abramson D, Simhkay L, Wobbekind D, and Mathiowitz E: Subcutaneous delivery of insulin loaded poly (fumaric-co-sebacic anhydride) microspheres to type 1 diabetic rats. Eur J Pharm Biopharm 2006;63:229-236.
30. Arora A, Hakim I, Baxter J, Ratnasingham R, Srinivasan R, Fletcher DA, and Mitragotri S: Needle-free delivery of macromolecules across the skin by nanoliter-volume pulsed microjets. Proc Natl Acad Sci USA. 2007;104:4255-4260.
31. Laube BL, Benedict GW, and Dobs AS: The lung as an alternative route of delivery for insulin in controlling postprandial glucose levels in patients with diabetes. Chest. 1998;114:1734-1739.
32. Skyler JS, Cefalu WT, Kourides IA, Landschulz WH, Balagtas CC, Cheng S, and Gelfand RA: Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomized proof-of-concept study. Lancet. 2001;357:331-335. (Pubitemid 32128537)
33. Capelleri JC, Cefalu WT, Rosenstock J, Kourides IA, and Gerber RA: Treatment satisfaction in type 2 diabetes: a comparison between an inhaled insulin regimen and a subcutaneous insulin regimen. Clin Ther. 2002;24:552-564.
34. Patton JS, Bukar JG, and Eldon MA: Clinical pharmaco-kinetics and pharmacodynamics of inhaled insulin. Clin Pharmacokinet. 2004;43:781-801.
35. Setter SM, Levien TL, Iltz JL, Odegard PS, Neumiller JJ, Baker DE, and Campbell RK: Inhaled dry powder insulin for the treatment of diabetes mellitus. Clin Ther. 2007;29:795-813.
36. Concessio NM, Van Oort MM, Knowles MR, and Hickey AJ: Pharmaceutical dry powder aerosols: correlation of powder properties with dose delivery and implications for phar-macodynamic effect. Pharm Res. 1999;16:828-834.
37. European Medicines Agency (EMEA): European Public Assessment Report\Exubera H-C-588-IA-09, 2007. Available at: http://www.emea.europa.eu= humandocs=PDFs=EPAR= exubera=058806en6.pdf
38. Heistracher T, and Hofmann W: Physiologically realistic models of bronchial airway bifurcations. J Aerosol Sci. 1995; 26:497-509.
39. Scherer PW, Shendalman LH, Greene NM, and Bouhuys A: Measurements of axial diffusivities in a model of the bronchial airways. J Appl Physiol. 1975;38:719-723.